Julie Cassecuel
YOU?
Author Swipe
View article: Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas
Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas Open
Background Solar factors play no role in the development of acral melanoma (AM). AM is characterized by low cumulative solar damage (low CSD). Responses to immunotherapy are correlated with mutational load, which, in turn, is correlated wi…
View article: NIVO-TIL: combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: an exploratory open-label phase I trial
NIVO-TIL: combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: an exploratory open-label phase I trial Open
I the proliferation of intra-tumour CD8+ T cells is directly correlated with the clinical response, making tumour-infiltrating lymphocytes (TILs) a treatment of interest in combination with a PD-1 inhibitor, which is the undisputed gold st…
View article: NIVO-TIL: Combination Anti-Pd-1 and Adoptive T-Cell Transfer in Untreated Metastatic Melanoma: An Exploratory Open-Label Phase I-II Trial
NIVO-TIL: Combination Anti-Pd-1 and Adoptive T-Cell Transfer in Untreated Metastatic Melanoma: An Exploratory Open-Label Phase I-II Trial Open
View article: NIVO-TIL: Combination anti-PD-1 and adoptive T-cell transfer in metastatic melanoma: a proof of concept
NIVO-TIL: Combination anti-PD-1 and adoptive T-cell transfer in metastatic melanoma: a proof of concept Open
Introduction : Metastatic melanoma patients responding to anti-PD-1 therapy showed proliferation of intra tumoral CD8+ T-cells directly correlated with clinical response, making Tumor-infiltrating lymphocytes (TILs) a potential curative tr…
View article: Impact of Doxycycline on COVID-19 Patients with Risk Factors: DYNAMIC, a Multi-Centre, Randomised, Placebo-Controlled, Double-Blind Trial
Impact of Doxycycline on COVID-19 Patients with Risk Factors: DYNAMIC, a Multi-Centre, Randomised, Placebo-Controlled, Double-Blind Trial Open
Background: The DYNAMIC study is based on three properties of tetracyclines. (1) Tetracyclines are known to chelate zinc from matrix metalloproteinases. It is possible their chelating activity may help inhibit COVID-19 infection by limitin…
View article: Impact of Doxycycline on COVID-19 Patients with Risk Factors: DYNAMIC, a Multi-Centre, Randomised, Placebo-Controlled, Double-Blind Trial
Impact of Doxycycline on COVID-19 Patients with Risk Factors: DYNAMIC, a Multi-Centre, Randomised, Placebo-Controlled, Double-Blind Trial Open
Background : The DYNAMIC study is based on three properties of tetracyclines. (1) Tetracyclines are known to chelate zinc from matrix metalloproteinases. It is possible their chelating activity may help inhibit COVID-19 infection by limiti…
View article: Impact of Doxycycline on COVID-19 Patients with Risk Factors: DYNAMIC, a Multi-Centre, Randomised, Placebo-Controlled, Double-Blind Trial
Impact of Doxycycline on COVID-19 Patients with Risk Factors: DYNAMIC, a Multi-Centre, Randomised, Placebo-Controlled, Double-Blind Trial Open
Background : The DYNAMIC study is based on three properties of tetracyclines. (1) Tetracyclines are known to chelate zinc from matrix metalloproteinases. It is possible their chelating activity may help inhibit COVID-19 infection by limiti…
View article: Impact of Doxycycline on Covid-19 Patients With Risk Factors of Disease Degradation: Dynamic, A Randomised Controlled Double-blind Trial
Impact of Doxycycline on Covid-19 Patients With Risk Factors of Disease Degradation: Dynamic, A Randomised Controlled Double-blind Trial Open
Background: The DYNAMIC study is based on three properties of tetracyclines. (1) Tetracyclines are known to chelate zinc from metalloproteases (MMPs). It is possible that their chelating activity may help to inhibit COVID-19 infection by l…